In the most recent publication from our team, Kawuma et al. employ a modelling approach
to characterize tenofovir’s pharmacokinetics when it is administered as two different prodrugs (TDF vs TAF). They developed a joint semi-mechanistic model that describes the population pharmacokinetics of tenofovir and which can foster further investigation of the use of the TAF prodrug. This model provides a framework for exposure predictions in patients, investigation of drug-drug interactions and simulation of alternative dosing regimens for further clinical trials that may be needed in the African context (for example within individuals co-infected with tuberculosis).
The publication can be found here.